Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume $2.73 +0.15 (+5.81%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Citius Pharmaceuticals Short Interest DataCitius Pharmaceuticals (CTXR) has a short interest of 603,700 shares, representing 8.38% of the float (the number of shares available for trading by the public). This marks a 12.23% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.8, indicating that it would take 2.8 days of the average trading volume of 103,317 shares to cover all short positions.Current Short Interest603,700 sharesPrevious Short Interest537,900 sharesChange Vs. Previous Month+12.23%Dollar Volume Sold Short$2.00 millionShort Interest Ratio2.8 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares7,229,000 sharesFloat Size7,200,000 sharesShort Percent of Float8.38%Today's Trading Volume130,509 sharesAverage Trading Volume103,317 sharesToday's Volume Vs. Average126% Short Selling Citius Pharmaceuticals? Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTXR Short Interest Over TimeCTXR Days to Cover Over TimeCTXR Percentage of Float Shorted Over Time Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Citius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024603,700 shares $2.00 million +12.2%8.4%2.8 $3.32 11/15/2024537,900 shares $2.69 million -95.4%7.5%2.8 $5.00 10/31/202411,790,000 shares $4.39 million -5.1%N/A10.5 $0.37 10/15/202412,420,000 shares $4.65 million -2.7%N/A8.9 $0.37 9/30/202412,770,000 shares $6.39 million +1.9%N/A7.2 $0.50 9/15/202412,530,000 shares $6.51 million -6.4%N/A5.8 $0.52 Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/202413,390,000 shares $7.63 million +9.0%N/A6.3 $0.57 8/15/202412,280,000 shares $7.20 million -16.1%N/A5.5 $0.59 7/31/202414,630,000 shares $13.24 million +21.9%N/A5.8 $0.91 7/15/202412,000,000 shares $9.18 million -15.2%N/A5.4 $0.77 6/30/202414,150,000 shares $8.26 million -8.5%N/A7.1 $0.58 6/15/202415,460,000 shares $9.67 million -2.8%N/A9.9 $0.63 5/31/202415,910,000 shares $11.10 million +9.9%N/A10.6 $0.70 5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62 4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75 4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77 3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90 3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74 2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77 2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84 1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62 1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75 12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76 12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80 11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77 11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77 10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75 10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70 9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68 9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76 8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91 8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86 7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99 7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19 6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20 6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26 5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16 5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28 4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45 4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17 3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03 2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15 2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23 1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39 1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12 12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79 12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13 11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17 11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07 10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08 10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08 9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21 9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23 8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23 8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27 7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89 7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91 6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92 6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95 5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94 5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90 4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01 4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55 3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79 3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58 2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54 2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63 1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51 1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53 12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54 12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70 11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69 11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81 10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87 10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09 9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03 9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03 8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25 8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81 7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89 7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92 6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48 6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23 5/28/202115,820,000 shares $36.07 million +8.6%12.9%2.5 $2.28 5/14/202114,570,000 shares $27.54 million +24.3%N/A1.7 $1.89 4/30/202111,720,000 shares $24.73 million -10.4%N/A0.8 $2.11 4/15/202113,080,000 shares $23.54 million +18.6%N/A0.9 $1.80 3/31/202111,030,000 shares $20.41 million +51.3%N/A0.8 $1.85 3/15/20217,290,000 shares $13.92 million -27.9%N/A0.6 $1.91Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 2/26/202110,110,000 shares $20.83 million +261.1%N/A0.9 $2.06 2/12/20212,800,000 shares $3.81 million +15.7%N/A0.3 $1.36 1/29/20212,420,000 shares $2.90 million +112.3%N/A1.6 $1.20 1/15/20211,140,000 shares $1.30 million -9.5%N/A1.4 $1.14 12/31/20201,260,000 shares $1.31 million -23.6%N/A1.8 $1.04 12/15/20201,650,000 shares $1.77 million +71.8%N/A2.2 $1.07 11/30/2020960,600 shares $947,824.02 -20.0%N/A1.2 $0.99 11/15/20201,200,000 shares $1.15 million -9.1%N/A1.6 $0.95 10/30/20201,320,000 shares $1.33 million +6.5%N/A1.6 $1.01 10/15/20201,240,000 shares $1.33 million +53.3%N/A1.1 $1.07 9/30/2020809,100 shares $841,464.00 +15.4%N/A0.6 $1.04 9/15/2020701,200 shares $743,272.00 -8.9%N/A0.2 $1.06 8/31/2020769,400 shares $715,542.00 +4.6%N/A0.3 $0.93 8/14/2020735,600 shares $787,092.00 -59.8%N/A0.2 $1.07 7/31/20201,830,000 shares $2.36 million +28.0%N/A0.5 $1.29 7/15/20201,430,000 shares $1.70 million -56.1%N/A0.4 $1.19 6/30/20203,260,000 shares $3.68 million +242.3%N/A1.1 $1.13 6/15/2020952,300 shares $842,595.04 +10.0%N/A0.6 $0.88 5/29/2020865,500 shares $751,254.00 -33.4%N/A0.6 $0.87 5/15/20201,300,000 shares $1.05 million +9.2%N/A1.1 $0.81 4/30/20201,190,000 shares $1.09 million +92.7%N/A1.4 $0.92 4/15/2020617,500 shares $432,188.25 +13.8%N/A0.9 $0.70 3/31/2020542,800 shares $439,668.00 +31.1%2.5%0.7 $0.81 3/13/2020414,200 shares $281,656.00 -5.2%1.9%0.8 $0.68 2/28/2020436,900 shares $200,974.00 -64.8%2.0%0.7 $0.46 2/14/20201,240,000 shares $731,600.00 +10.7%6.6%2 $0.59 1/31/20201,120,000 shares $896,000.00 +13.4%7.4%2 $0.80 1/15/2020988,000 shares $1.02 million -21.0%6.6%2 $1.03 12/31/20191,250,000 shares $1.56 million +303.5%8.3%3.5 $1.25 CTXR Short Interest - Frequently Asked Questions What is Citius Pharmaceuticals' current short interest? Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 603,700 shares of CTXR short. 8.38% of Citius Pharmaceuticals' shares are currently sold short. Learn More on Citius Pharmaceuticals' current short interest. What is a good short interest ratio for Citius Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTXR shares currently have a short interest ratio of 3.0. Learn More on Citius Pharmaceuticals's short interest ratio. What is a good short interest percentage for Citius Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.38% of Citius Pharmaceuticals' floating shares are currently sold short. Is Citius Pharmaceuticals' short interest increasing or decreasing? Citius Pharmaceuticals saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 603,700 shares, an increase of 12.2% from the previous total of 537,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Citius Pharmaceuticals' float size? Citius Pharmaceuticals currently has issued a total of 7,229,000 shares. Some of Citius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Citius Pharmaceuticals currently has a public float of 7,200,000 shares. How does Citius Pharmaceuticals' short interest compare to its competitors? 8.38% of Citius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Citius Pharmaceuticals: I-Mab (0.74%), Eliem Therapeutics, Inc. (2.22%), Generation Bio Co. (3.34%), Werewolf Therapeutics, Inc. (3.76%), Ovid Therapeutics Inc. (1.33%), FibroBiologics, Inc. (10.18%), Aerovate Therapeutics, Inc. (9.14%), ESSA Pharma Inc. (1.56%), PDS Biotechnology Co. (10.37%), OptiNose, Inc. (4.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Citius Pharmaceuticals stock? Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading up $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Citius Pharmaceuticals? A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further. How often is Citius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies I-Mab Short Interest Data Eliem Therapeutics Short Interest Data Generation Bio Short Interest Data Werewolf Therapeutics Short Interest Data Ovid Therapeutics Short Interest Data FibroBiologics Short Interest Data Aerovate Therapeutics Short Interest Data ESSA Pharma Short Interest Data PDS Biotechnology Short Interest Data OptiNose Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTXR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
